Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System.

Autor: Edelmann MR; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Isotope Synthesis, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.; Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K., Bredack C; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Discovery & Translational Medicine Area, Biomarker and Translational Technologies, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Belli S; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Pharmaceutical Science, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Mohr P; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Imhoff MP; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Reggiani F; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Kusznir EA; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Lead Discovery, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Rufer AC; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Lead Discovery, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Holt DP; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States., Valentine H; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States.; Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States., Wong DF; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States.; Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States.; Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21218, United States.; Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States.; ⧫Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States.; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States., Dannals RF; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, United States., Honer M; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Discovery & Translational Medicine Area, Biomarker and Translational Technologies, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland., Gobbi LC; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.
Jazyk: angličtina
Zdroj: Bioconjugate chemistry [Bioconjug Chem] 2023 Oct 18; Vol. 34 (10), pp. 1882-1893. Date of Electronic Publication: 2023 Sep 14.
DOI: 10.1021/acs.bioconjchem.3c00385
Abstrakt: The pretargeting approach separates the biological half-life of an antibody from the physical half-life of the radioisotope label, providing a strategy for reducing the radiation burden. A widely explored pretargeting approach makes use of the bioorthogonal click reaction between tetrazines (Tzs) and trans -cyclooctenes (TCOs), combining the targeting specificity of monoclonal antibodies (mAbs) with the rapid clearance and precise reaction of Tzs and TCOs. Such a strategy can allow for the targeting and imaging (e.g., by positron emission tomography (PET)) of molecular markers, which cannot be addressed by solely relying on small molecules. Tz derivatives that undergo inverse electron-demand Diels-Alder (IEDDA) reactions with an antibody bearing TCO moieties have been investigated. This study describes the synthesis and characterization of 11 cold Tz imaging agent candidates. These molecules have the potential to be radiolabeled with 18 F or 3 H, and with the former label, they could be of use as imaging tracers for positron emission tomography studies. Selection was made using a multiparameter optimization score for the central nervous system (CNS) PET tracers. Novel tetrazines were tested for their pH-dependent chemical stability. Those which turned out to be stable in a pH range of 6.5-8 were further characterized in in vitro assays with regard to their passive permeability, microsomal stability, and P-glycoprotein transport. Furthermore, selected Tzs were examined for their systemic clearance and CNS penetration in a single-dose pharmacokinetic study in rats. Two tetrazines were successfully labeled with 18 F, one of which showed brain penetration in a biodistribution study in mice. Another Tz was successfully tritium-labeled and used to demonstrate a bioorthogonal click reaction on a TCO-modified antibody. As a result, we identified one Tz as a potential fluorine-18-labeled CNS-PET agent and a second as a 3 H-radioligand for an IEDDA-based reaction with a modified brain-penetrating antibody.
Databáze: MEDLINE
Externí odkaz: